Works matching IS 03407004 AND DT 2024 AND VI 73 AND IP 8

Results: 25

Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03728-z

By:

Mallardo, Domenico;
Sparano, Francesca;
Vitale, Maria Grazia;
Trojaniello, Claudia;
Fordellone, Mario;
Cioli, Eleonora;
Esposito, Assunta;
Festino, Lucia;
Mallardo, Mario;
Vanella, Vito;
Facchini, Bianca Arianna;
De Filippi, Rosaria;
Meinardi, Paolo;
Ottaviano, Margaret;
Caracò, Corrado;
Simeone, Ester;
Ascierto, Paolo Antonio

Publication type:

Article

Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03747-w

By:

Liu, Chao;
Ruan, Yuli;
Huang, Rui;
Fang, Lin;
Wu, Tong;
Lv, Ying;
Cui, Luying;
Liao, Yuanyu;
Wang, Bojun;
Chen, Zhuo;
Su, Dan;
Ma, Yue;
Han, Shuling;
Guan, Xin;
Cui, Jie;
Yao, Yang;
Wang, Yao;
Wang, Mengmeng;
Liu, Ruiqi;
Zhang, Yanqiao

Publication type:

Article

Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03745-y

By:

Chen, Xinyuan;
Yu, Shuangni;
Chen, Jie;
Chen, Xianlong

Publication type:

Article

Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03743-0

By:

Deng, Ting;
Wang, Feixue;
Zhang, Le;
Ning, Tao;
Sun, Yansha;
Ge, Shaohua;
Bai, Ming;
Lu, Yao;
Li, Hongli;
Ba, Yi

Publication type:

Article

MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03742-1

By:

Park, Young Jin;
Kim, Suna;
Bang, Hyoju;
Kang, Seok Chan;
Cho, Sunjung;
Park, Jun-Eui;
Jung, Sungyoub;
Kim, Ha Hyung

Publication type:

Article

Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03738-x

By:

Liu, Aqing;
Zhang, Guan;
Yang, Yanjie;
Xia, Ying;
Li, Wentao;
Liu, Yunhe;
Cui, Qian;
Wang, Dong;
Yu, Jianchun

Publication type:

Article

SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03737-y

By:

Luo, Libo;
Jiang, Minlin;
Wu, Hong;
Liu, Yiqiang;
Wang, Haowei;
Zhou, Caicun;
Ren, Shengxiang;
Chen, Xiaoxia;
Jiang, Tao;
Xu, Chuan

Publication type:

Article

Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03735-0

By:

Zhang, Ruizhi;
Mao, Gan;
Tang, Yu;
Li, Chong;
Gao, Yisong;
Nie, Wenxiang;
Song, Tianyu;
Liu, Suao;
Zhang, Peng;
Tao, Kaixiong;
Li, Wei

Publication type:

Article

Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03734-1

By:

Chen, Yueying;
Han, Hedong;
Cheng, Jing;
Cheng, Qinpei;
Zhu, Suhua;
Zhan, Ping;
Liu, Hongbing;
Song, Yong;
Lv, Tangfeng

Publication type:

Article

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03733-2

By:

Kobayashi, Tomoko;
Iwama, Shintaro;
Yamagami, Ayana;
Izuchi, Tetsushi;
Suzuki, Koji;
Otake, Koki;
Yasuda, Yoshinori;
Ando, Masahiko;
Onoue, Takeshi;
Miyata, Takashi;
Sugiyama, Mariko;
Hagiwara, Daisuke;
Suga, Hidetaka;
Banno, Ryoichi;
Hase, Tetsunari;
Nishio, Naoki;
Mori, Shoichiro;
Shimokata, Tomoya;
Sano, Tomoyasu;
Niimi, Kaoru

Publication type:

Article

Combination of STING agonist with anti-vascular RGD-(KLAKLAK)<sub>2</sub> peptide as a novel anti-tumor therapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03732-3

By:

Czapla, Justyna;
Drzyzga, Alina;
Ciepła, Joanna;
Matuszczak, Sybilla;
Jarosz-Biej, Magdalena;
Pilny, Ewelina;
Cichoń, Tomasz;
Smolarczyk, Ryszard

Publication type:

Article

Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03731-4

By:

Nie, Haihang;
Yu, Yali;
Wang, Fan;
Huang, Xing;
Wang, Haizhou;
Wang, Jing;
Tao, Mi;
Ning, Yumei;
Zhou, JingKai;
Zhao, Qiu;
Xu, Fei;
Fang, Jun

Publication type:

Article

USP47 deficiency in mice modulates tumor infiltrating immune cells and enhances antitumor immune responses in prostate cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03730-5

By:

Wang, Qian-Lan;
Lu, Shun-Yuan;
Xu, Dan-Dan;
Ma, Jin-Xia;
Guo, Rui;
Zhang, Lu;
Tang, Ling-Yun;
Shen, Yan;
Shen, Chun-Ling;
Wang, Jin-Jin;
Wu, Ying-Li;
Lu, Li-Ming;
Wang, Zhu-Gang;
Zhang, Hong-Xin

Publication type:

Article

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03729-y

By:

Shen, Meiying;
Chen, Siyin;
Han, Xiaojian;
Hao, Yanan;
Wang, Junfan;
Li, Luo;
Chen, Tong;
Wang, Bozhi;
Zou, Lin;
Zhang, Tong;
Zhang, Wanli;
Han, Xiaxia;
Wang, Wang;
Yu, Haochen;
Li, Kang;
Liu, Shengchun;
Jin, Aishun

Publication type:

Article

Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03725-2

By:

Zhou, Yue;
Chu, Li;
Li, Shuyan;
Chu, Xiao;
Ni, Jianjiao;
Jiang, Shanshan;
Pang, Yechun;
Zheng, Danru;
Lu, Yujuan;
Lan, Fangcen;
Cai, Xiuyu;
Yang, Xi;
Zhu, Zhengfei

Publication type:

Article

Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03724-3

By:

Caii, Weimin;
Wu, Xiao;
Guo, Kun;
Chen, Yongxian;
Shi, Yubo;
Chen, Junkai

Publication type:

Article

Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancer.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03723-4

By:

Chen, Rongfa;
Liu, Linna;
Chen, Hui;
Xing, Chao;
Zhang, Tingting;
Pang, Yilin;
Yang, Xunjun

Publication type:

Article

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03721-6

By:

Sun, Yu-Ting;
Lu, Shi-Xun;
Lai, Ming-Yu;
Yang, Xia;
Guan, Wen-Long;
Yang, Li-Qiong;
Li, Yu-Hong;
Wang, Feng-Hua;
Yang, Da-Jun;
Qiu, Miao-Zhen

Publication type:

Article

Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03720-7

By:

Zhang, Jinmeng;
Gao, Jie;
Jiang, Shanshan;
Mao, Jiuang;
Chu, Li;
Chu, Xiao;
Yang, Xi;
Li, Yida;
Guo, Tiantian;
Zhou, Yue;
Xu, Dayu;
hu, Jie;
Chu, Qian;
Ni, Jianjiao;
Zhu, Zhengfei

Publication type:

Article

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03719-0

By:

Incorvaia, Lorena;
Monteiro, Fernando Sabino Marques;
Massari, Francesco;
Park, Se Hoon;
Roviello, Giandomenico;
Fiala, Ondřej;
Myint, Zin W.;
Kucharz, Jakub;
Molina-Cerrillo, Javier;
Santini, Daniele;
Buttner, Thomas;
Poprach, Alexandr;
Kopecky, Jindrich;
Zeppellini, Annalisa;
Pichler, Martin;
Buchler, Tomas;
Pichler, Renate;
Facchini, Gaetano;
Fay, Andre Poisl;
Soares, Andrey

Publication type:

Article

Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03718-1

By:

Wu, Shaoxian;
Jiang, Hongwei;
Fang, Zhang;
Wu, You;
Jiao, Jing;
Fang, Weiwei;
Wu, Yue;
Lang, Yanyan;
Chen, Ning;
Zhong, Ziyang;
Chen, Lujun;
Zheng, Xiao;
Lu, Binfeng;
Jiang, Jingting

Publication type:

Article

A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03713-6

By:

Zheng, Zehao;
Mei, Jie;
Guan, Renguo;
Zhang, Jiqi;
Xiong, Xinhao;
Gan, Junyu;
Li, Shaohua;
Guo, Rongping

Publication type:

Article

The biological roles of CD47 in ovarian cancer progression.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03708-3

By:

Xing, Linan;
Wang, Zhao;
Feng, Yue;
Luo, Haixia;
Dai, Guijiang;
Sang, Lin;
Zhang, Chunlong;
Qian, Jianhua

Publication type:

Article

Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03706-5

By:

Luo, Jiaojiao;
Ng, Wanyi;
Liu, Yangli;
Wang, Lixin;
Gong, Chenyuan;
Zhou, Yufu;
Fang, Cheng;
Zhu, Shiguo;
Yao, Chao

Publication type:

Article

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03701-w

By:

Olbromski, Mateusz;
Mrozowska, Monika;
Piotrowska, Aleksandra;
Smolarz, Beata;
Romanowicz, Hanna

Publication type:

Article